Atossa is dedicated to the millions of women, men and their families who have been devastated by breast cancer and other serious breast health conditions. At the heart of what we are doing is a strong belief that the best way to address breast cancer and other breast conditions is to reduce the risk of it occurring in the first place, and making it affordable.
We are developing COVID-19 therapies to treat both ends of the spectrum of this world-wide pandemic: AT-H201 for severely ill patients on ventilators, and AT-301 Nasal Spray for at-home use for patients who do not require hospitalization.
We are transforming the breast cancer paradigm by developing the promise of endoxifen and exploiting its potential to both help prevent as well as to treat breast cancer with our proprietary Topical and Oral Endoxifen. We are also developing a new method to deliver immunotherapies (such as CAR-T) by using our proprietary intraductal microcatheter technology to deliver the therapy through the breast ducts directly to the site of the cancer.
We are striving to maintain the quality of life for prostate cancer patients starting their androgen deprivation therapy through the use of our Topical Endoxifen to reduce the occurrence of gynecomastia.
We are using an international strategy to achieve our vision. Our pre-clinical studies are being conducted in the U.S., while our clinical studies are underway in the U.S., Australia and Sweden. We have established drug manufacturing capabilities in Taiwan as well as the U.S.
We invite you to learn more about our Company and unique approach by reading through our web site.